do peptides FAQ

Not all CIRS cases respond to immune modulation alone. Roughly 30% of patients have concurrent genetic polymorphisms (MTHFR, COMT, GST variants) that impair detoxification pathways independent of immune function. No amount of Treg upregulation will clear mycotoxins if phase II liver conjugation is compromised. If TGF-β1, MMP-9, or C4a remain elevated after 8–12 weeks on a structured peptide protocol, the next step is functional genomics testing and targeted support for methylation or glutathione synthesis pathways. Peptides address immune dysregulation, not enzymatic bottlenecks.

Most physicians won't prescribe peptides for PTLDS because no FDA-approved indication exists for this use. Thymosin alpha-1 is FDA-approved for hepatitis B and C. Off-label prescribing for immune dysfunction is at physician discretion. Compounded peptides from 503B facilities like Real Peptides are available for research purposes but require understanding of reconstitution, dosing, and injection protocols. Functional medicine practitioners and integrative physicians are more likely to consider peptide protocols for post-infectious immune dysfunction than conventional infectious disease specialists.

Yes, but the combination is redundant and risks melatonin oversupply. Epithalon increases endogenous melatonin production, while exogenous melatonin supplements provide synthetic melatonin. Taking both simultaneously can produce excessive melatonin levels (>10 mg circulating), which paradoxically delays sleep onset and causes next-morning grogginess. If using epithalon, discontinue exogenous melatonin supplementation or reduce it to ≤1 mg. Monitor subjective sleep quality and adjust based on response. The goal is optimised melatonin rhythm, not maximal melatonin dose.

Switch to an intermittent dosing schedule or rotate peptides. Hexarelin and GHRP-6 are known to cause receptor desensitisation after 4–6 weeks of continuous use, reducing GH output by 40–60%. Ipamorelin and CJC-1295 show significantly less tachyphylaxis, but if reduced response is observed, a 5-days-on, 2-days-off protocol allows GHSR-1a receptors to resensitise. Alternatively, rotating between different GHS classes (GHRH analogs vs ghrelin mimetics) every 8–12 weeks prevents receptor downregulation without interrupting the study timeline. MK-677 is less prone to tachyphylaxis than injectable GHRPs but still benefits from periodic cycling.

Combining peptides with herbal antimicrobials like Japanese knotweed or cat's claw is common in integrative Lyme treatment. The mechanisms don't overlap. Herbs target residual bacterial load or biofilm disruption, while peptides modulate immune recovery. Monitor for additive immune activation: if you're already using immune-stimulating herbs (Andrographis, Sida acuta), adding thymosin alpha-1 could temporarily worsen inflammatory symptoms through cytokine release. Start peptides at half-dose if combining with strong immune-activating herbs and titrate based on symptom response.

Reassess the injury type and consider imaging. Peptides help with shoulder injury involving soft tissue damage but don't address structural issues requiring surgical repair. Full-thickness rotator cuff tears larger than 3 cm, displaced labral tears with mechanical catching, or grade III AC joint separations won't heal with peptide therapy alone regardless of protocol duration. If pain persists or function hasn't improved measurably by week 6, obtain MRI evaluation to rule out surgical indications. Peptides accelerate healing in repairable tissue. They don't replace anatomical reconstruction.

Do not use it. Cloudiness indicates bacterial contamination or peptide aggregation. Both render the compound inactive or unsafe. Lyophilised peptides should reconstitute into a clear, colourless solution. Discolouration (yellow, brown, pink) suggests oxidative degradation or impurity. Contact the supplier immediately. At Real Peptides, every batch undergoes sterility testing and HPLC verification before shipping. Contamination is rare with proper sourcing.

Extend the protocol to 12–16 weeks before concluding non-response. Immune recalibration requires sustained signaling. Six weeks is insufficient for most patients in published trials. If fatigue persists beyond 16 weeks at therapeutic dose (1.6–3.2mg twice weekly), thymosin alpha-1 likely isn't addressing your specific dysfunction. ME/CFS heterogeneity means not all patients have the same immune profile; peptides targeting T-cell function won't help if your fatigue stems primarily from mitochondrial or neuroendocrine causes.

Discard it immediately. Cloudiness indicates aggregation or contamination. Injecting compromised peptide introduces infection risk without therapeutic benefit. Properly reconstituted peptides remain clear to slightly opalescent. Cloudiness, visible particulates, or discoloration all signal degradation. This happens when bacteriostatic water isn't sterile, when vials are shaken rather than gently swirled, or when storage temperature exceeded 8°C. There's no salvaging a cloudy solution.

Most peptides don't have direct pharmacokinetic interactions with stimulants (amphetamines, methylphenidate) or cholinergics (donepezil, rivastigmine), but the combination can amplify side effects or mask underlying issues. Growth hormone secretagogues like MK 677 increase appetite and can cause insulin resistance. Combining with stimulants that suppress appetite creates conflicting metabolic signals. Cerebrolysin's neurotrophic effects are synergistic with acetylcholinesterase inhibitors in dementia treatment, but the combination requires medical supervision. If you're on prescription cognitive enhancers, peptide addition should be discussed with your prescribing physician. Not because of contraindication risk, but because outcome tracking becomes impossible without knowing which agent is driving observed changes.

No. Peptide-induced melanin persists as long as the melanin-containing keratinocytes remain in the epidermis. Most users maintain visible pigmentation for 2–4 weeks after the last dose, fading gradually as keratinocytes turn over and slough off. The fade rate matches natural skin cell turnover. Faster on the face (14–21 days) than the torso or limbs (28–35 days). You can extend the tan with maintenance dosing (0.25mg twice weekly), which keeps melanocyte activity elevated without continuous daily administration.

Yes, but expect a transition period. Minoxidil works by prolonging anagen through potassium channel opening and increased blood flow. Stopping it abruptly triggers shedding as follicles that were artificially held in anagen shift to telogen. If you transition to peptides, overlap the treatments for 8–12 weeks: continue minoxidil while introducing peptides twice daily, then taper minoxidil over 4 weeks. This reduces rebound shedding. Peptides won't prevent all shedding during the transition, but they can shorten the telogen phase and accelerate re-entry into anagen.

MK 677 increases appetite and insulin resistance in approximately 25% of users by elevating ghrelin persistently rather than in pulses. If fasting glucose rises above 100mg/dL or you experience reactive hypoglycemia, discontinue MK 677 and switch to a pulsatile GHRP like ipamorelin. The glucose effect is dose-dependent. Lowering from 25mg to 10mg often mitigates it while retaining GH-stimulating benefits.

No. Receptor saturation occurs around 1.0–1.5mg for most individuals, beyond which additional melanin synthesis plateaus. Doubling the dose increases side effect incidence (nausea, flushing) without proportionally increasing pigmentation. The rate-limiting step is tyrosinase enzyme activity and keratinocyte turnover, not receptor occupancy. Melanin deposition follows a biological timeline that cannot be accelerated beyond your skin's natural keratinocyte migration rate from basal layer to surface, which takes 28–40 days regardless of peptide dose.

Hexarelin shows the strongest desensitisation, losing efficacy after 4–6 weeks of continuous daily use due to GHS-R1a receptor downregulation. GHRP-2 and ipamorelin maintain response longer. Most research protocols run 8–12 weeks before cycling off for 4–6 weeks to allow receptor resensitisation. Modified GRF(1-29) and CJC-1295 show minimal tachyphylaxis because GHRH receptors downregulate less aggressively. Rotating between peptide classes every 8–12 weeks is the standard approach for extended use.

PT-141 shows 62% response rates in SSRI-induced sexual dysfunction because the mechanism bypasses serotonin-mediated inhibition of dopamine pathways. SSRIs suppress libido and erectile function by increasing serotonin tone in the prefrontal cortex, which dampens dopaminergic reward signaling. PT-141 directly activates downstream melanocortin pathways that don't depend on dopamine availability. The hypothalamic signal propagates regardless of SSRI interference. The alternative is switching to bupropion (which enhances dopamine rather than serotonin) or adding low-dose aripiprazole as a serotonin modulator, but both require psychiatric consultation and carry their own side effect profiles.

Melanotan II activates MC1R receptors in melanocytes in addition to MC4R in the brain, causing irreversible skin darkening that PT-141 (which is selective for MC3R and MC4R) avoids. The broader receptor activation increases side effect burden. Flushing, spontaneous erections, and nausea occur more frequently. If libido is the primary goal, PT-141 is the refined, targeted version developed specifically to isolate the sexual arousal effect without melanogenesis. Melanotan II is not FDA-approved and is banned in Australia and the UK due to safety concerns.

Peptides help with thinning hair caused by follicle dormancy, not hormonal miniaturization. If your hair loss is androgenetic alopecia driven by DHT sensitivity, peptides alone will not stop progression. They will improve density of existing miniaturized hairs but won't block the underlying hormonal signal. The most effective protocol for genetic hair loss combines DHT inhibition (finasteride or dutasteride) with peptide signaling to maximize follicle response. Peptides without DHT control in androgenetic alopecia is like fertilizing a garden while the weeds keep spreading.

No direct drug interactions between peptides and standard IBD medications have been documented in published research, but combination protocols lack formal safety testing. BPC-157 and KPV operate through distinct mechanisms from TNF-α blockers or corticosteroids, suggesting additive rather than antagonistic effects. Institutions exploring combination therapy typically maintain baseline immunosuppressant doses and add peptides as adjunct treatment, monitoring inflammatory markers every four weeks.

Peptides signal immune cell behaviour. They don't provide the raw materials (amino acids, vitamins, minerals) cells need to execute those signals. Thymosin alpha-1 tells T-cells to mature, but if the body lacks adequate glutamine, zinc, or vitamin D, the cells can't complete differentiation regardless of the peptide signal. Think of peptides as the blueprint and nutrients as the building materials. Both are required. Discontinuing foundational nutrition while adding peptides produces suboptimal outcomes. Research shows thymosin alpha-1 efficacy improves 22% when paired with adequate protein intake (1.6g/kg) and vitamin D sufficiency (>30 ng/mL serum 25-OH-D).